634 related articles for article (PubMed ID: 10391682)
1. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.
Kortylewski M; Heinrich PC; Mackiewicz A; Schniertshauer U; Klingmüller U; Nakajima K; Hirano T; Horn F; Behrmann I
Oncogene; 1999 Jun; 18(25):3742-53. PubMed ID: 10391682
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma.
Flørenes VA; Lu C; Bhattacharya N; Rak J; Sheehan C; Slingerland JM; Kerbel RS
Oncogene; 1999 Jan; 18(4):1023-32. PubMed ID: 10023678
[TBL] [Abstract][Full Text] [Related]
3. Involvement of tyrosine phosphatase PTP1D in the inhibition of interleukin-6-induced Stat3 signaling by alpha-thrombin.
Gunaje JJ; Bhat GJ
Biochem Biophys Res Commun; 2001 Oct; 288(1):252-7. PubMed ID: 11594781
[TBL] [Abstract][Full Text] [Related]
4. STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1).
de Koning JP; Soede-Bobok AA; Ward AC; Schelen AM; Antonissen C; van Leeuwen D; Löwenberg B; Touw IP
Oncogene; 2000 Jul; 19(29):3290-8. PubMed ID: 10918585
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-9 (IL-9) induces cell growth arrest associated with sustained signal transducer and activator of transcription activation in lymphoma cells overexpressing the IL-9 receptor.
Demoulin JB; Van Snick J; Renauld JC
Cell Growth Differ; 2001 Mar; 12(3):169-74. PubMed ID: 11306517
[TBL] [Abstract][Full Text] [Related]
6. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells.
Klausen P; Pedersen L; Jurlander J; Baumann H
Oncogene; 2000 Jul; 19(32):3675-83. PubMed ID: 10951574
[TBL] [Abstract][Full Text] [Related]
7. MEK/ERK and signal transducer and activator of transcription signaling pathways modulate oncostatin M-stimulated CCL2 expression in human osteoblasts through a common transcription factor.
Lin SK; Kok SH; Yeh FT; Kuo MY; Lin CC; Wang CC; Goldring SR; Hong CY
Arthritis Rheum; 2004 Mar; 50(3):785-93. PubMed ID: 15022320
[TBL] [Abstract][Full Text] [Related]
8. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.
Blanchard F; Kinzie E; Wang Y; Duplomb L; Godard A; Held WA; Asch BB; Baumann H
Oncogene; 2002 Sep; 21(41):6264-77. PubMed ID: 12214267
[TBL] [Abstract][Full Text] [Related]
9. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells.
Grant SL; Hammacher A; Douglas AM; Goss GA; Mansfield RK; Heath JK; Begley CG
Oncogene; 2002 Jan; 21(3):460-74. PubMed ID: 11821958
[TBL] [Abstract][Full Text] [Related]
10. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.
Kim H; Baumann H
Mol Cell Biol; 1999 Aug; 19(8):5326-38. PubMed ID: 10409724
[TBL] [Abstract][Full Text] [Related]
11. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation.
Yamanaka Y; Nakajima K; Fukada T; Hibi M; Hirano T
EMBO J; 1996 Apr; 15(7):1557-65. PubMed ID: 8612579
[TBL] [Abstract][Full Text] [Related]
12. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family.
Montero-Julian FA; Brailly H; Sautès C; Joyeux I; Dorval T; Mosseri V; Yasukawa K; Wijdenes J; Adler A; Gorin I; Fridman WH; Tartour E
Clin Cancer Res; 1997 Aug; 3(8):1443-51. PubMed ID: 9815830
[TBL] [Abstract][Full Text] [Related]
13. Differential inhibition of IL-6-type cytokine-induced STAT activation by PMA.
Terstegen L; Maassen BG; Radtke S; Behrmann I; Schaper F; Heinrich PC; Graeve L; Gatsios P
FEBS Lett; 2000 Jul; 478(1-2):100-4. PubMed ID: 10922477
[TBL] [Abstract][Full Text] [Related]
14. Modulation of hepatic acute phase gene expression by epidermal growth factor and Src protein tyrosine kinases in murine and human hepatic cells.
Wang Y; Ripperger J; Fey GH; Samols D; Kordula T; Wetzler M; Van Etten RA; Baumann H
Hepatology; 1999 Sep; 30(3):682-97. PubMed ID: 10462375
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3.
Chipoy C; Berreur M; Couillaud S; Pradal G; Vallette F; Colombeix C; Rédini F; Heymann D; Blanchard F
J Bone Miner Res; 2004 Nov; 19(11):1850-61. PubMed ID: 15476586
[TBL] [Abstract][Full Text] [Related]
16. Activation of the Jak-Stat- and MAPK-pathways by oncostatin M is not sufficient to cause growth inhibition of human glioma cells.
Halfter H; Postert C; Friedrich M; Ringelstein EB; Stögbauer F
Brain Res Mol Brain Res; 2000 Sep; 80(2):198-206. PubMed ID: 11038252
[TBL] [Abstract][Full Text] [Related]
17. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression.
Reichert TE; Nagashima S; Kashii Y; Stanson J; Gao G; Dou QP; Whiteside TL
Oncogene; 2000 Jan; 19(4):514-25. PubMed ID: 10698521
[TBL] [Abstract][Full Text] [Related]
19. Activation of gp130 transduces hypertrophic signal through interaction of scaffolding/docking protein Gab1 with tyrosine phosphatase SHP2 in cardiomyocytes.
Nakaoka Y; Nishida K; Fujio Y; Izumi M; Terai K; Oshima Y; Sugiyama S; Matsuda S; Koyasu S; Yamauchi-Takihara K; Hirano T; Kawase I; Hirota H
Circ Res; 2003 Aug; 93(3):221-9. PubMed ID: 12855672
[TBL] [Abstract][Full Text] [Related]
20. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor.
Mori S; Murakami-Mori K; Bonavida B
Anticancer Res; 1999; 19(2A):1011-5. PubMed ID: 10368647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
